Green & Sustainable Science

Developing innovative, cost-efficient manufacturing processes with low environmental impact aligns with our company’s environmental sustainability strategy.

Highlights

Honored by the American Chemistry Society (ACS) as one of five winners of the Green Chemistry Challenge Awards

Our approach

Green and sustainable science is the design of new products and processes that reduce or eliminate the use or generation of hazardous substances.

The concept applies across the life cycle of a product, including its design, manufacture, use and ultimate disposal.

There is a trend towards more regulatory restrictions and increased oversight in many places around the world. Our strategy to develop green and sustainable commercial chemical route development could help to avoid potential future issues in the supply chain.

Our company’s overall objective is to be viewed as the leader in the industry for the development of innovative, efficient, green and sustainable commercial syntheses of our small molecule active pharmaceutical ingredients (API). We are also exploring ways to reduce the environmental impact of biologics and vaccine manufacturing.

GoalsProgressIndicator
Green and sustainable science
By 2020, at least 90 percent of our new human health API processes will meet internal sustainability targets at launch.
On track to establish and meet targets that will drive improvements in the material efficiency of our new products
On Track

Governance

Our company’s Process Research and Development department is responsible for chemistry development. The progress toward our goals is overseen by various internal bodies including the Scientific Advisory Council (SAC) and the API Oversight Council (APIOC).

Strategy

Our integrated strategy involves several stages and aims to provide innovative solutions rather than incremental improvements to historical practices. We see science and innovation as critical enablers to developing sustainable, low-cost manufacturing processes that provide both environmental and economic benefits over the life cycles of our products.

By using more efficient and innovative processing methods and technologies, we are reducing the amount of energy, water and raw materials we use to make our products, thereby minimizing the amount of waste we generate and lowering our production costs.

We aim to develop the most efficient and sustainable processes at product launch, with the goal of minimizing material use and waste from our commercial manufacturing. Our company’s Research Laboratories (MRL) utilize an innovative “green-by-design” development strategy to progress from an initial early clinical supply route to a fully optimized and sustainable commercial manufacturing process. We have set a target to ensure that by 2020 at least 90 percent of our human health API processes will meet internal sustainability targets at the time of product launch.

Programs and initiatives

As part of our Green & Sustainable Science program, we calculate the process mass intensity (PMI) of our human health products. PMI represents the number of kilograms of raw materials (including water) used to produce one kilogram of an API or biologic. PMI indicates how efficiently we convert raw materials into final products. We use this metric internally to compare different manufacturing methods, identify process improvement opportunities and track our progress. We are also using life-cycle assessment (LCA) tools to further evaluate the environmental impacts of our processes.

American Chemistry Society (ACS) Green Chemistry Institute (GCI)

We are a founding member of the ACS Green Chemistry Institute® Pharmaceutical Roundtable, a partnership between the ACS GCI and member pharmaceutical companies. The Roundtable assists with the development of tools such as solvent selection and reagent guides and the PMI calculator, which drive the integration of sustainability into process design. Roundtable members also work together to support and advance academic research and education on new ways to apply green and sustainable science to pharmaceutical discovery and manufacture, which have resulted in several industry publications on more sustainable processes and technologies. More recently, the ACS GCI member companies have developed tools and guidelines for sustainable production practices relevant to bioprocessing.

In 2018, and again in 2019, our company was honored by the ACS as one of five winners of the Green Chemistry Challenge Awards. In 2018, our scientists were recognized for successfully applying green chemistry design principles to the commercial synthesis of PIFELTRO™ (doravirine), an antiviral drug approved in 2018 in the U.S. and Europe.

In 2019, we were recognized for changing the way we manufacture ceftolozane, a component of the antibiotic ZERBAXA® (ceftolozane and tazobactam).

Since the establishment of the annual Green Chemistry Challenge Awards in 1996, we have been the only pharmaceutical company to be recognized with six Green Chemistry Awards for innovative process improvements.